WSI Co., Ltd.
Financials
Valuation Metrics
WSI Co., Ltd.'s Market Cap is ₩535B. At end of 2025 it was ₩1218B. Ranked #1693 of 2,436 in KR market (top 69%), #1017 of 1,649 on KOSDAQ (top 62%), #70 of 96 in Health Care Equipment & Services (top 73%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 53.55B KRW | KR#1,693/2,436 Sec#70/96 |
| Revenue | 50.83B KRW | KR#1,768/2,436 Sec#51/96 |
| Net Income | -4.38B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 87.07B KRW | KR#1,851/2,436 Sec#57/96 |
| Net Assets | 62.61B KRW | KR#1,718/2,436 Sec#53/96 |
| Employees | 33 | KR#2,157/2,436 Sec#83/96 |
| Value | ||
| P/B | 0.86x | KR#1,346/2,436 Sec#27/96 |
| P/S | 1.05x | KR#1,430/2,436 Sec#30/96 |
| EV/EBITDA | 25.27x | KR#1,125/2,436 Sec#36/96 |
| FCF Yield | 4.03% | KR#936/2,436 Sec#25/96 |
| Profitability | ||
| ROE | -6.99% | KR#1,811/2,436 Sec#60/96 |
| ROA | -5.03% | KR#1,896/2,436 Sec#63/96 |
| Op. Margin | 5.30% | KR#892/2,436 Sec#40/96 |
| Revenue Growth | -6.85% | KR#1,764/2,436 Sec#70/96 |
| Earnings Growth | -107.20% | KR#1,382/2,436 Sec#46/96 |
| Financial Health | ||
| Debt Ratio | 139.07% | KR#1,017/2,436 Sec#50/96 |
| Total Debt | 21.50B KRW | KR#1,328/2,436 Sec#38/96 |
| FCF | 2.16B KRW | KR#1,069/2,436 Sec#31/96 |
| Cash | 6.97B KRW | KR#1,864/2,436 Sec#63/96 |
| Current Ratio | 2.81x | KR#662/2,436 Sec#38/96 |
| Net Debt/EBITDA | 5.39x | KR#1,108/2,436 Sec#43/96 |
| Performance | ||
| 1Y Return | -16.07% | KR#1,138/2,436 Sec#32/96 |
| 1M Return | -6.45% | KR#1,519/2,436 Sec#64/96 |
| From 52W High | -74.20% | KR#2,262/2,436 Sec#87/96 |
| 1Y MDD | -74.14% | KR#2,107/2,436 Sec#79/96 |
| Trading | ||
| Volume | 160,505 shares | KR#684/2,436 Sec#26/96 |
| Foreign Own. | 5.21% | KR#754/2,436 Sec#25/96 |
| Per Share | ||
| EPS | -112 KRW | KR—/2,436 Sec—/96 |
| BPS | 1,443 KRW | KR#2,177/2,436 Sec#78/96 |
Company Info
Established in 2016, WSI was listed on KOSDAQ in 2020 following its merger with IBKS No.10 Special Purpose Acquisition Company. The company's main business is the distribution of spinal and joint medical devices. In 2024, WSI acquired a 67% stake in pharmaceutical company Introbio Pharma, adding pharmaceutical manufacturing and R&D, with plans to acquire an additional 10% in the first half of 2025. Headquartered in Songpa-gu, Seoul, WSI is also entering the cardiovascular interventional medical device market from 2024 through collaboration with a global cardiac disease medical device company.